Treatment outcomes for early-stage lung cancer after pre-surgery therapy
Part of Cancer, Lungs & breathing clinical trials.
This trial looks at how well different treatments work before surgery for early-stage non-small cell lung cancer (NSCLC). It aims to help doctors understand which pre-surgery therapies lead to the best outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage I, II, or III non-small cell lung cancer (the most common type).
- You have had surgery to remove the lung cancer.
- Before surgery, you received chemotherapy, targeted therapy, or immunotherapy (alone or together).
- You do not have another active cancer that required treatment in the last two years.
- All your medical details (like cancer stage and treatment history) are available in your records.
- You are not in another trial where the treatment you receive is unknown.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a treatment given before surgery for non-small cell lung cancer. Patients receive chemotherapy plus immunotherapy (chemo-immunotherapy) first, then have surgery to remove the tumor. The goal is to see how well this approach works.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This study tests whether giving a combination of three medicines before surgery can help shrink tumors in people with stage 2 or 3 non-small cell lung cancer, potentially making surgery and recovery more effective. The medicines include an immunotherapy drug (tislelizumab), a targeted therapy (anlotinib), and a chemotherapy drug (nab-paclitaxel).
This trial tests a combination of three treatments given before surgery for lung cancer: targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib). The goal is to shrink the tumor and improve the chance of successful surgery.
This trial tests giving chemotherapy, immunotherapy, and targeted radiation before surgery for people with non-small cell lung cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial tests whether combining chemo or targeted therapy before surgery can help people with non-small cell lung cancer that may require removing a whole lung. We want to see if this approach makes the surgery safer and more effective.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.